Results 11 to 20 of about 11,372 (280)
Efficacy of liposomal amphotericin B and anidulafungin using an antifungal lock technique (ALT) for catheter-related Candida albicans and Candida glabrata infections in an experimental model. [PDF]
PLoS ONE, 2019 ObjectiveThe aims of this study were as follows. First, we sought to compare the in vitro susceptibility of liposomal amphotericin B (LAmB) and anidulafungin on Candida albicans and Candida glabrata biofilms growing on silicone discs.
Jana Basas +4 more
doaj +7 more sources
Anidulafungin-Induced Suicidal Erythrocyte Death [PDF]
Cellular Physiology and Biochemistry, 2016 Background/Aims: The novel antifungal drug Anidulafungin is used for the treatment of diverse fungal infections including candidiasis and aspergillosis.
Thomas Peter +3 more
doaj +3 more sources
Human Tissue Distribution of Anidulafungin and Micafungin
Antimicrobial Agents and Chemotherapy, 2021 Concentrations of anidulafungin and micafungin were determined in eight different tissues obtained during autopsy of four deceased individuals who had been treated with anidulafungin and of seven who had received micafungin.
J. Marx +5 more
semanticscholar +4 more sources
Journal of Fungi, 2020 Rezafungin is a next-generation echinocandin that has favorable pharmacokinetic properties. We compared the occurrence of paradoxical growth (PG) and trailing effect (TE) characteristics to echinocadins with rezafungin, caspofungin, micafungin and ...
Zoltán Tóth +9 more
doaj +2 more sources
Comparison of antifungal drugs in the treatment of invasive pulmonary aspergillosis: a systematic review and network meta-analysis [PDF]
Frontiers in MicrobiologyBackgroundVoriconazole, isavuconazole, and amphotericin (AmB) formulations are currently recommended to treat invasive pulmonary aspergillosis (IPA).
Jing Cheng +5 more
doaj +2 more sources
Anidulafungin and its role in candida infections
Infection and Drug Resistance, 2009 Diane M Cappelletty, Rose JungThe University of Toledo, College of Pharmacy, Toledo, OH, USAAbstract: Candida infections continue to play a significant role not only in critically ill and immunocompromised patients but also in non-compromised patients ...
Diane M Cappelletty, Rose Jung
doaj +5 more sources
Pharmacokinetics of Anidulafungin in Obese and Normal-Weight Adults [PDF]
Antimicrobial Agents and Chemotherapy, 2018 In 2025, approximately one out of five adults will be obese. Physiological changes associated with obesity have been shown to influence the pharmacokinetics of drugs.
R. Wasmann +6 more
semanticscholar +6 more sources
Safety of anidulafungin in solid organ transplant recipients [PDF]
Liver Transplantation, 2012 The aim of this study was the evaluation of the safety of anidulafungin in adult solid organ transplantation (SOT) recipients. During the study period (14 months), we included all consecutive SOT recipients from 14 centers who received anidulafungin for at least 48 hours for the treatment of invasive fungal infections (IFIs ...
José María Aguado +10 more
openalex +6 more sources
Optimizing anidulafungin exposure across a wide adult body size range
Antimicrobial Agents and Chemotherapy, 2023 Echinocandins like anidulafungin are first-line therapies for candidemia and invasive candidiasis, but their dosing may be suboptimal in obese patients.
Ronald G. Hall +5 more
semanticscholar +1 more source
bioRxiv, 2022 Candida auris is an emerging, multidrug-resistant fungal pathogen that causes refractory colonization and life-threatening, invasive nosocomial infections. The high proportion of C.
L. L. John +6 more
semanticscholar +1 more source